BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average rating of “Buy” by the ten analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $9.00.

Several research firms recently commented on BCRX. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Saturday, May 6th. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, May 19th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/biocryst-pharmaceuticals-inc-bcrx-receives-average-rating-of-buy-from-analysts.html.

A number of institutional investors have recently made changes to their positions in BCRX. Principal Financial Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares during the last quarter. Comerica Bank increased its position in shares of BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock worth $100,000 after buying an additional 2,552 shares during the last quarter. Legal & General Group Plc increased its position in shares of BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after buying an additional 860 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $126,000. Finally, Bank of America Corp DE increased its position in shares of BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares during the last quarter. Institutional investors own 84.49% of the company’s stock.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 1.81% on Tuesday, hitting $4.50. 620,143 shares of the company traded hands. BioCryst Pharmaceuticals has a 12 month low of $3.73 and a 12 month high of $9.25. The company’s market capitalization is $361.89 million. The stock’s 50-day moving average price is $5.61 and its 200-day moving average price is $6.36.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $5.79 million. During the same quarter last year, the company earned ($0.22) EPS. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals will post ($0.72) earnings per share for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.